Literature DB >> 10506407

Principles of transcutaneous immunization using cholera toxin as an adjuvant.

T Scharton-Kersten1, G M Glenn, R Vassell, J Yu, D Walwender, C R Alving.   

Abstract

Transcutaneous immunization is a novel strategy for immunization employing topical application of antigen and adjuvant to the skin surface and resulting in detectable antigen/adjuvant specific IgG in plasma and mucosal secretions. In this study we show that transcutaneous immunization with cholera toxin (CT) as an adjuvant can be used in several inbred mouse strains with varying H-2 major histocompatibility complex genes (C57BL/6 (H-2(b)), BALB/c (H-2(d)), and C3H (H-2(k))). Although the primary anti-CT antibody responses reflected previously described MHC restriction patterns for this protein, the differences were overcome after two booster immunizations. Potent antibody responses against hen egg lysozyme and/or diphtheria toxoid were observed using CT as adjuvant. We also demonstrate that the unshaved dorsal or ventral surface of the ear can be effectively used for transcutaneous immunization and that gentle swabbing with alcohol increases the magnitude of the host immune response. Together these data further our understanding of the principles governing this new platform technology and support its integration into novel and existing human vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506407     DOI: 10.1016/s0264-410x(99)00233-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  New vaccine development.

Authors:  Gregory A Poland; Dennis Murray; Ruben Bonilla-Guerrero
Journal:  BMJ       Date:  2002-06-01

2.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  Immunological activation following transcutaneous delivery of HR-gp100 protein.

Authors:  Shoshana Frankenburg; Igor Grinberg; Ziva Bazak; Lena Fingerut; Jacob Pitcovski; Raphael Gorodetsky; Tamar Peretz; Ram M Spira; Yehuda Skornik; Ronald S Goldstein
Journal:  Vaccine       Date:  2007-04-25       Impact factor: 3.641

Review 4.  An update on the use of laser technology in skin vaccination.

Authors:  Xinyuan Chen; Ji Wang; Dilip Shah; Mei X Wu
Journal:  Expert Rev Vaccines       Date:  2013-10-16       Impact factor: 5.217

5.  Novel antigen delivery technologies: a review.

Authors:  Deepika Jain; Vikas Jain; Ranjit Singh
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

6.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

7.  Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection.

Authors:  Linda J Berry; Danica K Hickey; Kathryn A Skelding; Shisan Bao; Amanda M Rendina; Philip M Hansbro; Christine M Gockel; Kenneth W Beagley
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

8.  Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.

Authors:  A S Beignon; J P Briand; S Muller; C D Partidos
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

9.  Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.

Authors:  Joshua Arrington; Ralph P Braun; Lichun Dong; Deborah H Fuller; Michael D Macklin; Scott W Umlauf; Sarah J Wagner; Mary S Wu; Lendon G Payne; Joel R Haynes
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

10.  Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.

Authors:  T Scharton-Kersten; J m Yu; R Vassell; D O'Hagan; C R Alving; G M Glenn
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.